6.3.6. persistent psa radical prostatectomy. five 20% men continue detectable persistent psa rp (when defined majority studies detectable post-rp psa ≥ 0.1 ng/ml within 4 8 weeks surgery) . may result persistent local disease, pre-existing metastases residual benign prostate tissue. 6.3.6.1. natural history persistently elevated psa rp several studies shown persistent psa rp associated advanced disease (such positive surgical margins, pathologic stage ≥ t3a, positive nodal status and/or pathologic isup grade group > 3) poor prognosis. initially defined ≥ 0.1 ng/ml, improvements sensitivity psa assays allow detection psa much lower levels. moreira et al., demonstrated failure achieve psa less 0.03 ng/ml within six months surgery associated increased risk bcr overall mortality . however, since majority published literature based 0.1 ng/ml psa cut-off, significantly longterm data definition. predictors psa persistence higher bmi, higher pre-operative psa isup grade group ≥ 3 . patients psa persistence, one 5-year bcr-free survival 68% 36%, compared 95% 72%, respectively, men without psa persistence . ten-year os patients without psa persistence 63% 80%, respectively. spratt et al., confirmed persistently detectable psa rp represents one worst prognostic factors associated oncological outcome . 150 patients persistent psa, 95% received rt detectable metastasis. multi-variable analysis presence persistently detectable psa post-rp associated 4-fold increase risk developing metastasis. confirmed data preisser et al., showed persistent psa prognostic increased risk metastasis death . 15 years rp, mfs rates, os css rates 53.0 vs. 93.2% (p < 0.001), 64.7 vs. 81.2% (p < 0.001) 75.5 vs. 96.2% (p < 0.001) persistent vs. undetectable psa, respectively. median follow-up 61.8 months patients undetectable psa vs. 46.4 months patients persistent psa. multivariable cox regression models, persistent psa represented independent predictor metastasis (hr: 3.59, p < 0.001), death (hr: 1.86, p < 0.001) cancer-specific death (hr: 3.15, p < 0.001). however, patients persistent psa rp experience disease recurrence. xiang et al., showed 50% 5-year bcr-free survival men persistent psa level > 0.1 ≤ 0.2 ng/ml 6–8 weeks rp . rogers et al., assessed clinical outcome 160 men persistently detectable psa level rp . patient received adjuvant therapy documented metastasis. study, 38% patients evidence metastases ≥ 7 years 32% patients reported develop metastases within 3 years. noteworthy significant proportion patients low-risk disease. multi-variable analysis psa slope rp (as calculated using psa levels 3 twelve months surgery) pathological isup grade group significantly associated development distant metastases. 6.3.6.2. imaging patients persistently elevated psa rp standard imaging bone scan mri low detection rate men psa 2 ng/ml. however, psma pet/ct shown identify residual cancer positivity rates 33%, 46%, 57%, 82%, 97%, men post-rp psa ranges 0–0.19, 0.2–0.49, 0.5–0.99, 1–1.99, ≥ 2 ng/ml, respectively [867-872] guide srt planning . based post-rp psa ranges, schmidt-hegemann et al., studied 129 patients either persistent psa (52%) bcr (48%) rp, showing men persistent psa significantly pelvic nodal involvement psma pet/ct developing detectable psa . multi-centre retrospective study including 191 patients, 68ga-psma localised biochemical persistence rp two-thirds patients high-risk pca features. obturator presacral mesorectal nodes identified high risk residual disease . another retrospective study included 150 patients persistent psa rarp re-staged 68ga-psma 18f-dcfpyl psma. authors found presence persistent psa majority patients already metastatic pelvic lns distant metastases would support role psma pet/ ct imaging guiding (salvage) treatment strategies . present uncertainty regarding best treatment psma pet/ct shows metastatic disease outside pelvis. 6.3.6.3. impact post-operative rt and/or adt patients persistent psa benefit srt patients persistent psa remains unclear due lack rcts, however, would appear men persistent psa less well men bcr undergoing rt. preisser et al., compared oncological outcomes patients persistent psa received srt vs. . subgroup patients persistent psa, 1:1 propensity score matching patients srt vs. rt, os rates ten years rp 86.6 vs. 72.6% entire cohort (p < 0.01), 86.3 vs. 60.0% patients positive surgical margin (p = 0.02), 77.8 vs. 49.0% pt3b disease (p < 0.001), 79.3 vs. 55.8% isup grade group 1 disease (p < 0.01) 87.4 vs. 50.5% pn1 disease (p < 0.01), respectively. moreover, css rates ten years rp 93.7 vs. 81.6% entire cohort (p < 0.01), 90.8 vs. 69.7% patients positive surgical margin (p = 0.04), 82.7 vs. 55.3% pt3b disease (p < 0.01), 85.4 vs. 69.7% isup grade group 1 disease (p < 0.01) 96.2 vs. 55.8% pn1 disease (p < 0.01), srt vs. rt, respectively. multivariable models, 1:1 propensity score matching, srt associated lower risk death (hr: 0.42, p = 0.02) lower cancer-specific death (hr: 0.29, p = 0.03). survival outcomes patients persistent psa underwent srt suggest benefit outcomes worse men experiencing bcr . clear number studies poor outcomes driven level pre-rt psa, presence isup grade group ≥ 4 rp histology pt3b disease [878-883]. fossati et al., suggested men persistent psa rp isup grade group ≤ 3 benefit significantly , although supported preisser et al. . current data allow making clear treatment decisions. addition adt may improve pfs . choo et al., studied addition 2-year adt immediate rt prostate bed patients pt3 and/or positive surgical margins rp . twenty-nine 78 included patients persistently detectable post-operative psa. relapse-free rate 85% five years 68% 7 years, superior 5-year progression-free estimates 74% 61% post-operative rt arms eortc swog studies, respectively, included patients undetectable psa rp . patients persistently detectable post-operative psa comprised approximately 50% 12%, respectively, study cohorts eortc swog studies. aro 96-02, prospective rct, 74 patients psa persistence (20%) received immediate srt (66 gy per protocol [arm c]). 10-year clinical relapse-free survival 63% . getug-22 trial comparing rt rt plus short-term adt post-rp psa persistence (0.2–2.0 ng/ml) reported good tolerability combined treatment. oncological endpoints yet published . two srs addressing persistent psa confirmed strong correlation psa persistence poor oncologic outcomes . ploussard et al., also reported srt associated improved survival outcomes, although available evidence low quality . 6.3.6.4. conclusion available data suggest patients psa persistence rp may benefit early aggressive multi-modality treatment, however, lack prospective rcts makes firm recommendations difficult. 6.3.6.5. recommendations management persistent psa radical prostatectomy recommendationsstrength ratingoffer prostate-specific membrane antigen (psma) positron emission tomography/computed tomography (pet/ct scan men persistent prostate-specific antigen (psa) > 0.2 ng/ml results influence subsequent treatment decisions.weaktreat men evidence metastatic disease salvage radiotherapy additional hormonal therapy.weak